title: Mechanisms of fetal and neonatal renal impairment by pharmacologic inhibition of angiotensin.
abstract: The renin-angiotensin system is highly conserved through evolutionary history, and has multiple functions in addition to maintaining cardiovascular homeostasis: these include the regulation of renal cell survival and cell death, and development of the kidney. The importance of angiotensin (ANG) in normal kidney development was first recognized in infants with renal maldevelopment born to mothers treated with angiotensin converting enzyme (ACE) inhibitors or with ANG AT1 receptor blockers. The molecular role of ANG in renal development has been elucidated using gene targeting in mice, revealing major effects in branching morphogenesis, vasculogenesis, development of the papilla and renal concentrating mechanism. Although exposure of the fetus to ANG inhibitors is potentially harmful throughout pregnancy, effects are greater in late compared to early gestation. Significant differences between humans and rodents in placental transfer of ANG and timing of renal development contributed to initial delays in recognizing the teratogenic effects of ANG inhibitors. Although administration of ACE or AT1 receptor inhibitors can slow progression of renal disease in older children, ANG inhibition in the neonatal period can aggravate renal injury due to congenital urinary tract obstruction. Neonates are also far more sensitive than older children to the hypotensive actions these agents and doses must be markedly reduced to avoid precipitating oliguria. Understanding the complex interactions of the maturing renin-angiotensin system in the perinatal period is essential in the use of ANG or renin inhibitors in women during childbearing years or in neonates with cardiovascular or renal disease.
authors.affiliation: Department of Pediatrics, University of Virginia, Box 800386, Charlottesville, VA 22908, USA. RLC2M@virginia.edu
authors.forename: Robert L
authors.initials: RL
authors.lastname: Chevalier
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D000809:Angiotensins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D005075:Biological Evolution; D005260:Female; D047109:Fetal Development / Q000187:drug effects; D005865:Gestational Age; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism*; D051379:Mice; D007703:Peptidyl-Dipeptidase A / Q000737:chemistry / Q000378:metabolism; D011247:Pregnancy; D051381:Rats; D044140:Receptor, Angiotensin, Type 1 / Q000737:chemistry / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000809:Angiotensins; D000959:Antihypertensive Agents; D044140:Receptor, Angiotensin, Type 1; D007703:Peptidyl-Dipeptidase A